Literature DB >> 21508354

Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines.

Cao Yang1, Edwin Choy, Francis J Hornicek, Kirkham B Wood, Joseph H Schwab, Xianzhe Liu, Henry Mankin, Zhenfeng Duan.   

Abstract

The antitumor activity of histone deacetylase inhibitors (HDACI) on multidrug-resistant sarcoma cell lines has not been previously described. Treatment of multidrug-resistant sarcoma cell lines with HDACI PCI-24781 resulted in dose-dependent accumulation of acetylated histone, p21 and poly(ADP-ribose)polymerase (PARP) cleavage products. Growth of these cell lines was inhibited by PCI-24781 at IC(50) of 0.43 to 2.7. When we looked for synergy of PCI-24781 with chemotherapeutic agents, we found that PCI-24781 reverses drug resistance in all four multidrug-resistant sarcoma cell lines and synergizes with chemotherapeutic agents to enhance caspase-3/-7 activity. Expression of RAD51 (a marker for DNA double-strand break repair) was inhibited and the expression of GADD45α (a marker for growth arrest and DNA-damage) was induced by PCI-24781 in multidrug-resistant sarcoma cell lines. In conclusion, HDACI PCI-24781 synergizes with chemotherapeutic drugs to induce apoptosis and reverses drug resistance in multidrug-resistant sarcoma cell lines.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21508354      PMCID： PMC3744220     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  37 in total

Review 1.  Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes.

Authors:  Harvey W Mohrenweiser; David M Wilson; Irene M Jones
Journal:  Mutat Res       Date:  2003-05-15       Impact factor: 2.433

2.  Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling.

Authors:  Christophe F Deroanne; Karine Bonjean; Sandrine Servotte; Laetitia Devy; Alain Colige; Nathalie Clausse; Sylvia Blacher; Eric Verdin; Jean-Michel Foidart; Betty V Nusgens; Vincent Castronovo
Journal:  Oncogene       Date:  2002-01-17       Impact factor: 9.867

3.  Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.

Authors:  Keith B Glaser; Michael J Staver; Jeffrey F Waring; Joshua Stender; Roger G Ulrich; Steven K Davidsen
Journal:  Mol Cancer Ther       Date:  2003-02       Impact factor: 6.261

4.  Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.

Authors:  Zhenfeng Duan; Katherine A Brakora; Michael V Seiden
Journal:  Mol Cancer Ther       Date:  2004-07       Impact factor: 6.261

5.  Multidrug resistant osteosarcoma cell lines exhibit deficiency of GADD45alpha expression.

Authors:  Cao Yang; Shuhua Yang; Kirkham B Wood; Francis J Hornicek; Joseph H Schwab; Gertrude Fondren; Henry Mankin; Zhenfeng Duan
Journal:  Apoptosis       Date:  2009-01       Impact factor: 4.677

6.  Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.

Authors:  Lianne Fuino; Purva Bali; Sylvie Wittmann; Sreenivas Donapaty; Fei Guo; Hirohito Yamaguchi; Hong-Gang Wang; Peter Atadja; Kapil Bhalla
Journal:  Mol Cancer Ther       Date:  2003-10       Impact factor: 6.261

Review 7.  Strategies for reversing drug resistance.

Authors:  Tito Fojo; Susan Bates
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

8.  Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.

Authors:  Roberto R Rosato; Jorge A Almenara; Yun Dai; Steven Grant
Journal:  Mol Cancer Ther       Date:  2003-12       Impact factor: 6.261

9.  Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.

Authors:  Myoung Sook Kim; Mellissa Blake; Jin Hyen Baek; Glenda Kohlhagen; Yves Pommier; France Carrier
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

Review 10.  Molecular targets in therapy for human soft-tissue and bone sarcomas.

Authors:  Dejka M Steinert; L Johnetta Blakely; Jason Salganick; Jonathan C Trent
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.945
View more
  13 in total

Review 1.  Therapeutic applications of histone deacetylase inhibitors in sarcoma.

Authors:  Fan Tang; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2017-07-06       Impact factor: 12.111

2.  SIRT1 is a critical regulator of K562 cell growth, survival, and differentiation.

Authors:  Mark T Duncan; Teresa A DeLuca; Hsin-Yu Kuo; Minchang Yi; Milan Mrksich; William M Miller
Journal:  Exp Cell Res       Date:  2016-04-13       Impact factor: 3.905

3.  mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops.

Authors:  Karina Galoian; H T Temple; Armen Galoyan
Journal:  Tumour Biol       Date:  2012-01-14

4.  RAD51 potentiates synergistic effects of chemotherapy with PCI-24781 and cis-diamminedichloroplatinum on gastric cancer.

Authors:  Wei-Ling He; Yu-Huang Li; Wei-Jian Hou; Zun-Fu Ke; Xin-Lin Chen; Li-Ya Lu; Shi-Rong Cai; Wu Song; Chang-Hua Zhang; Yu-Long He
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  Role of epigenetic modulation for the treatment of sarcoma.

Authors:  Gregory M Cote; Edwin Choy
Journal:  Curr Treat Options Oncol       Date:  2013-09

6.  Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.

Authors:  Edwin Choy; Yael Flamand; Sriram Balasubramanian; James E Butrynski; David C Harmon; Suzanne George; Gregory M Cote; Andrew J Wagner; Jeffrey A Morgan; Mint Sirisawad; Chitra Mani; Francis J Hornicek; Zhenfeng Duan; George D Demetri
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

7.  Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.

Authors:  Franck Morschhauser; Louis Terriou; Bertrand Coiffier; Emmanuel Bachy; Andrea Varga; Ioana Kloos; Hélène Lelièvre; Anne-Laure Sarry; Stéphane Depil; Vincent Ribrag
Journal:  Invest New Drugs       Date:  2015-01-21       Impact factor: 3.850

8.  Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies.

Authors:  Antonino Grassadonia; Pasquale Cioffi; Felice Simiele; Laura Iezzi; Marinella Zilli; Clara Natoli
Journal:  Cancers (Basel)       Date:  2013-07-25       Impact factor: 6.639

9.  Dipyrithione induces cell-cycle arrest and apoptosis in four cancer cell lines in vitro and inhibits tumor growth in a mouse model.

Authors:  Yumei Fan; Caizhi Liu; Yongmao Huang; Jie Zhang; Linlin Cai; Shengnan Wang; Yongze Zhang; Xianglin Duan; Zhimin Yin
Journal:  BMC Pharmacol Toxicol       Date:  2013-10-21       Impact factor: 2.483

10.  The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines.

Authors:  Pamela Viani de Andrade; Augusto Faria Andrade; Rosane Gomes de Paula Queiroz; Carlos Alberto Scrideli; Luiz Gonzaga Tone; Elvis Terci Valera
Journal:  Cancer Cell Int       Date:  2016-04-18       Impact factor: 5.722
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.